Ceredex Value Advisors LLC Reduces Position in Revvity Inc. $RVTY

Key Points

• Ceredex Value Advisors LLC significantly reduced its stake in Revvity Inc. by 54.9%, now holding approximately 386,785 shares valued at $40.9 million after selling 471,108 shares in the past quarter.
• Analysts have lowered their ratings and target prices for Revvity, with JPMorgan and Goldman Sachs adjusting their targets from $120 to $100 and $140 to $125, respectively, indicating cautious outlooks on the stock.
• Revvity recently reported better-than-expected quarterly earnings, with an EPS of $1.18 compared to the consensus estimate of $1.14, alongside a dividend announcement of $0.07 per share to be paid in November.

Ceredex Value Advisors LLC decreased its holdings in Revvity Inc. (NYSE:RVTY - Free Report) by 54.9% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 386,785 shares of the company's stock after selling 471,108 shares during the quarter. Ceredex Value Advisors LLC owned 0.33% of Revvity worth $40,922,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of the company. Optiver Holding B.V. purchased a new stake in shares of Revvity during the fourth quarter valued at $33,000. Quarry LP raised its stake in shares of Revvity by 45.7% during the 4th quarter. Quarry LP now owns 303 shares of the company's stock worth $34,000 after purchasing an additional 95 shares in the last quarter. Vermillion Wealth Management Inc. acquired a new position in shares of Revvity during the 4th quarter valued at about $41,000. New Age Alpha Advisors LLC acquired a new stake in Revvity in the 1st quarter valued at approximately $44,000. Finally, Continuum Advisory LLC grew its holdings in shares of Revvity by 39.3% during the 4th quarter. Continuum Advisory LLC now owns 471 shares of the company's stock worth $53,000 after purchasing an additional 133 shares in the last quarter. Institutional investors own 86.65% of the company's stock.

Analyst Upgrades and Downgrades

RVTY has been the subject of several research reports. Evercore ISI lowered their target price on Revvity from $116.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Stifel Nicolaus cut their price target on Revvity from $120.00 to $110.00 and set a "hold" rating on the stock in a report on Tuesday, July 29th. Raymond James Financial reissued an "outperform" rating and set a $115.00 price target (down previously from $120.00) on shares of Revvity in a research report on Tuesday, July 29th. Bank of America reduced their price target on Revvity from $116.00 to $110.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Finally, Wall Street Zen cut Revvity from a "buy" rating to a "hold" rating in a research note on Sunday, August 3rd. Ten investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $120.07.

Revvity Stock Performance

Shares of NYSE:RVTY traded up $0.98 during mid-day trading on Friday, reaching $90.21. The company had a trading volume of 786,177 shares, compared to its average volume of 1,179,008. The company's 50-day moving average price is $94.11 and its 200-day moving average price is $98.11. The company has a current ratio of 3.33, a quick ratio of 2.75 and a debt-to-equity ratio of 0.43. Revvity Inc. has a one year low of $85.12 and a one year high of $129.50. The firm has a market cap of $10.47 billion, a price-to-earnings ratio of 38.23, a PEG ratio of 2.38 and a beta of 0.91.

Revvity (NYSE:RVTY - Get Free Report) last announced its earnings results on Monday, July 28th. The company reported $1.18 earnings per share for the quarter, topping analysts' consensus estimates of $1.14 by $0.04. Revvity had a return on equity of 7.66% and a net margin of 10.19%.The business had revenue of $720.28 million for the quarter, compared to analyst estimates of $711.26 million. During the same period in the prior year, the company earned $1.22 EPS. The company's quarterly revenue was up 4.1% compared to the same quarter last year. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. As a group, equities research analysts anticipate that Revvity Inc. will post 4.94 EPS for the current fiscal year.

Revvity Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 17th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. Revvity's dividend payout ratio (DPR) is 11.86%.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.